Company

While working in colon cancer research and bioinformatics, Wei became fascinated by the genome’s complexity and by the lack of tools capable of studying it at scale. At DNA chip pioneer Affymetrix, he became Vice President of Advanced Technology and Intellectual Property. Before founding Centrillion, he was a partner at Wilson Sonsini Goodrich & Rosati, where he advised technology startups. He also cofounded Sentieon, a bioinformatics software company. At Centrillion, Wei learned from semiconductor veterans how precision manufacturing works at scale and collaborated with organizations including Taiwan’s Industrial Technology Research Institute to build an operating fab. Many nights in the fab and countless rounds of troubleshooting gave him a deep appreciation for the art of light-directed synthesis and chip making. He continues to be energized by the convergence of AI and large scale biology.

EducationPh.D., Virginia Tech; Postdoctoral Fellow, Emory University School of Medicine; J.D., Stanford University

Glenn and Wei first worked together during the formative years of DNA chip technology. After early work in DNA based diagnostics at Syva, Glenn joined Stephen Fodor’s team at Affymax to develop the first commercial photolithographic DNA arrays. He continued at Affymetrix as Director of Chemistry and Process Development and later Vice President of Chemistry and Process Technologies, helping turn efficient surface synthesis chemistry into a scalable platform. Reunited at Centrillion, he leads chemistry and process technology for a new generation of high-density, wafer-scale synthesis.

EducationPh.D., McGill University; Postdoctoral Fellow, Massachusetts Institute of Technology

Filip came to Centrillion through the recommendation of his Stanford advisor, Professor Fabian Pease. He works where chip architecture meets the factory floor, connecting engineering with wafer-scale process innovation. He has been instrumental in platform and manufacturing development. Among his many inventions is SpinCell, which makes automated photodirected DNA synthesis possible.

EducationPh.D., Stanford University

Jeremy joined Centrillion because of a shared vision for genomics: moving beyond isolated variants toward decoding entire genomes. As a postdoctoral fellow in George Church’s laboratory at Harvard Medical School, he worked on emerging next generation sequencing technologies. He later served as Chair of the Department of Chemistry and Chemical Biology at the University of New Mexico, where his work bridges biology, bioinformatics, and engineering.

AffiliationProfessor at The University of New Mexico and Co-Director of the Bioinformatics Shared Resource at the UNM Comprehensive Cancer Center

EducationPh.D., University of California, San Diego; Postdoctoral Fellow, Harvard Medical School

Peter first became part of Centrillion as an investor representing the ARM IoT Fund. A visionary in the practical use of computing, he brought experience in edge computing, vision AI, and AI chip design to biology long before AI became fashionable. Before the large language model breakthrough, he saw that artificial intelligence and life sciences were on a path to converge and became a driving force behind that connection at Centrillion. His more than 40 years of experience include serving as President of Arm Taiwan and Vice President of Innovation and Investment, establishing Arm’s first Asia Design Center, and leading Freescale design centers in China. Earlier, he helped build the first single chip CMOS RISC microprocessor at IBM Watson and was a founder or founding team member of several Silicon Valley companies, including an early fabless PC chipset company. His work has connected semiconductor innovation with universities, governments, and emerging applications including healthcare and IoT.

AffiliationARM IoT Fund

EducationPh.D., Massachusetts Institute of Technology

Matt’s path to Centrillion began in digital health and as an investor representative. His conviction in the underlying DNA chip technology expanded his role into company leadership and the direction of research. A former Global Vice President at IBM who later led Cybernaut International, he brings experience in big data, artificial intelligence, cloud platforms, AI enabled healthcare, and international market development.

EducationPh.D., Vanderbilt University; M.B.A., George Washington University